Your Messages Inbox
Your Article Summary
See Latest ArticlesTwo first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers
Clinical Therapeutics, 05/20/09
White B et al. - Administered intravenously or subcu-taneously, MEDI-528 had an acceptable safety profile and exhibited linear pharmacokinetics over the dose range studied in healthy adults in these Phase I studies. The findings support further investigation of MEDI-528 in multiple-dose trials in patients with asthma.
Related Articles
Clinical importance of identifying immunoglobulin E-mediated disease in patients with Asthma
Clinical Cornerstone, 10/01/09
Relevance Score: 96%
Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma
Osteoporosis International, 10/13/09
Relevance Score: 95%
The Saudi Initiative for asthma
Annals of Thoracic Medicine, 10/13/09
Relevance Score: 95%
Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study
Journal of Allergy and Clinical Immunology, 10/09/09
Relevance Score: 95%
Identification of Asthma Phenotypes using Cluster Analysis in the Severe Asthma Research Program
American Journal of Respiratory and Critical Care Medicine, 11/09/09
Relevance Score: 94%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09
Article Search
Sponsor